ALLO
ALLO clinical trials: Allogene Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Allogene Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 9
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ALLO on the catalyst calendar · ALLO registry changes
- Primary completion Feb 2028Sponsor estimatePhase 1NCT07085104A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseaseAllogene Therapeutics · Systemic Lupus Erythematosus (With and Without Nephritis)RecruitingALLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT06500273Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLAllogene Therapeutics · Large B-cell LymphomaRecruitingALLOLeadNTRACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2039Sponsor estimateNo phase registeredNCT06925685Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell ProductAllogene Therapeutics · Hematologic MalignanciesEnrolling by invitationALLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2030Sponsor estimatePhase 1NCT04696731Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaAllogene Therapeutics · Advanced/Metastatic Clear Cell Renal Cell CarcinomaActive, not recruitingALLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 27, 2025ActualPhase 1NCT04093596Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)Allogene Therapeutics · Relapsed/Refractory Multiple MyelomaCompletedALLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2029Sponsor estimatePhase 1/Phase 2NCT04416984Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic...Allogene Therapeutics · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaActive, not recruitingALLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2021ActualPhase 1NCT03939026Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular LymphomaAllogene Therapeutics · Relapsed/Refractory Large B Cell LymphomaCompletedALLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 20, 2024ActualPhase 2NCT05714345Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyAllogene Therapeutics · Relapsed/Refractory Large B Cell LymphomaTerminatedALLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 11, 2023ActualPhase 1/Phase 2NCT05000450Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaAllogene Therapeutics · Relapsed/Refractory Multiple MyelomaTerminatedALLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner